ALK-Abelló A/S (CPH:ALK.B)

Denmark flag Denmark · Delayed Price · Currency is DKK
228.60
+0.20 (0.09%)
At close: Dec 30, 2025
42.70%
Market Cap50.56B
Revenue (ttm)6.08B
Net Income (ttm)1.10B
Shares Out221.19M
EPS (ttm)4.97
PE Ratio45.95
Forward PE37.75
Dividendn/a
Ex-Dividend Daten/a
Volume120,067
Average Volume180,717
Open227.00
Previous Close228.40
Day's Range226.80 - 230.40
52-Week Range130.70 - 237.60
Beta0.65
RSI56.87
Earnings DateFeb 20, 2026

About ALK-Abelló

ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including house dust mites, grass and tree pollen, ragweed, Japanese cedar, and food. It also provides consumer healt... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1923
Employees 2,753
Stock Exchange Copenhagen Stock Exchange
Ticker Symbol ALK.B
Full Company Profile

Financial Performance

In 2024, ALK-Abelló's revenue was 5.54 billion, an increase of 14.78% compared to the previous year's 4.82 billion. Earnings were 815.00 million, an increase of 67.70%.

Financial Statements

News

Alk-Abello AS (AKBLF) Q3 2025 Earnings Call Highlights: Robust Revenue and Earnings Growth Amid ...

Alk-Abello AS (AKBLF) Q3 2025 Earnings Call Highlights: Robust Revenue and Earnings Growth Amid Strategic Expansions

7 weeks ago - GuruFocus

Alk-Abello AS (AKBLF) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Improved Margins

Alk-Abello AS (AKBLF) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Improved Margins

1 year ago - GuruFocus